Revolutionizing Immunotherapy with Universal SNAP-CAR

Discover the future of targeted cancer treatment with our groundbreaking SNAP-CAR technology, designed to adapt and conquer multiple antigens with unmatched precision.

About Snap Biosciences

Founded on the pioneering research from the University of Pittsburgh, Snap Biosciences has been at the forefront of immunotherapy innovation since August 2022. Our Universal SNAP-CAR platform, initially licensed in 2022, has expanded to include NK cells and autoimmune disease applications. This versatile technology allows for the use of a single, off-the-shelf cell bank to target multiple antigens, revolutionizing treatments for hematological malignancies, solid tumors, and autoimmune diseases. Our mission is to harness the power of immune effector cells to provide adaptable, effective therapies for a wide range of conditions.

Key Features of SNAP-CAR Technology

Antigen Agnostic Platform

Our SNAP-CAR technology is designed to be antigen agnostic, allowing it to target a wide range of antigens with unparalleled flexibility.

Tagged Antibody Utilization

By using tagged antibodies, SNAP-CAR can direct antigen specificity, making it adaptable for multiple indications and enhancing treatment precision.

Versatile Application

SNAP-CAR’s universal immune effector cell can be used across various indications, including hematological malignancies, solid tumors, and autoimmune diseases.

Get in Touch with Snap Bio-Science

Discover how SNAP-CAR technology can revolutionize your treatment approach. Contact us for more information, sign up for updates, or explore our innovative product offerings today.